Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute on Alcohol Abuse and Alcoholism (NIAAA) )
ClinicalTrials.gov Identifier:
NCT00896038
First received: May 8, 2009
Last updated: October 5, 2015
Last verified: October 2015
Results First Received: May 26, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Conditions: Alcoholism
Alcohol Dependence
Posttraumatic Stress Disorder
Interventions: Drug: Aprepitant
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Aprepitant Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant daily for 21 days
Placebo Subjects received placebo during the 1-week placebo lead-in and then daily for 21 days

Participant Flow:   Overall Study
    Aprepitant   Placebo
STARTED   30   28 
COMPLETED   26   27 
NOT COMPLETED   4   1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Aprepitant Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant daily for 21 days
Placebo Subjects received placebo during the 1-week placebo lead-in and then daily for 21 days
Total Total of all reporting groups

Baseline Measures
   Aprepitant   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 30   28   58 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   30   28   58 
>=65 years   0   0   0 
Gender 
[Units: Participants]
     
Female   14   13   27 
Male   16   15   31 
Ethnicity (NIH/OMB) 
[Units: Participants]
     
Hispanic or Latino   0   2   2 
Not Hispanic or Latino   30   26   56 
Unknown or Not Reported   0   0   0 
Race (NIH/OMB) 
[Units: Participants]
     
American Indian or Alaska Native   0   1   1 
Asian   0   0   0 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   14   14   28 
White   16   12   28 
More than one race   0   0   0 
Unknown or Not Reported   0   1   1 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Alcohol Craving in Response to the Stress Script   [ Time Frame: 15 minutes prior to the beginning of stress script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

2.  Primary:   Alcohol Craving in Response to the Stress Script   [ Time Frame: 5 minutes after the beginning of stress script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

3.  Primary:   Alcohol Craving in Response to the Stress Script   [ Time Frame: 15 minutes after the beginning of stress script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

4.  Primary:   Alcohol Craving in Response to the Stress Script   [ Time Frame: 30 minutes after the beginning of stress script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

5.  Primary:   Alcohol Craving in Response to the Stress Script   [ Time Frame: 45 minutes after the beginning of stress script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

6.  Primary:   Alcohol Craving in Response to the Stress Script   [ Time Frame: 60 minutes after the beginning of stress script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

7.  Primary:   Alcohol Craving in Response to the Stress Script   [ Time Frame: 75 minutes after the beginning of stress script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

8.  Primary:   Alcohol Craving in Response to the Stress Script   [ Time Frame: 90 minutes after the beginning of stress script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

9.  Primary:   Alcohol Craving in Response to the Alcohol Cue Script   [ Time Frame: 15 minutes prior to the beginning of alcohol script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

10.  Primary:   Alcohol Craving in Response to the Alcohol Cue Script   [ Time Frame: 5 minutes after the beginning of alcohol script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

11.  Primary:   Alcohol Craving in Response to the Alcohol Cue Script   [ Time Frame: 15 minutes after the beginning of alcohol script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

12.  Primary:   Alcohol Craving in Response to the Alcohol Cue Script   [ Time Frame: 30 minutes after the beginning of alcohol script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

13.  Primary:   Alcohol Craving in Response to the Alcohol Cue Script   [ Time Frame: 45 minutes after the beginning of alcohol script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

14.  Primary:   Alcohol Craving in Response to the Alcohol Cue Script   [ Time Frame: 60 minutes after the beginning of alcohol script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

15.  Primary:   Alcohol Craving in Response to the Alcohol Cue Script   [ Time Frame: 75 minutes after the beginning of alcohol script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

16.  Primary:   Alcohol Craving in Response to the Alcohol Cue Script   [ Time Frame: 90 minutes after the beginning of alcohol script presentation, which occurred on Day 25, 26, or 27 of the treatment period ]

17.  Primary:   PTSD Total Symptom Severity Score   [ Time Frame: Day 29 of the treatment period, 2 days after the final script presentation ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Melanie Schwandt
Organization: National Institute on Alcohol Abuse and Alcoholism
phone: 3014516960
e-mail: melanies@mail.nih.gov


Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute on Alcohol Abuse and Alcoholism (NIAAA) )
ClinicalTrials.gov Identifier: NCT00896038     History of Changes
Other Study ID Numbers: 090136
09-AA-0136 ( Other Identifier: NIHCC )
Study First Received: May 8, 2009
Results First Received: May 26, 2015
Last Updated: October 5, 2015
Health Authority: United States: Federal Government
United States: Food and Drug Administration